Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
ICU Medical makes the disposable tubes, catheters, pumps, and IV products hospitals use to deliver fluids and medicine to patients.
ICU Medical sells the everyday hardware of a hospital bed: the plastic tubing, catheters, and connectors that carry fluids and drugs into a patient's veins, the pumps that push those fluids at the right speed, and the swabs and other products used to keep IV lines clean. When you lie in a hospital with an IV in your arm, there's a decent chance several pieces of that setup came from this company.
Its biggest business is infusion consumables — the single-use stuff that gets thrown away and reordered constantly, which makes for steady, recurring revenue. On top of that it sells infusion systems, the electronic pumps and software that control how fast medicine drips in, and a smaller vital-care line. Hospitals buy from ICU Medical because the products plug into one another and into the pumps nurses already know how to use; switching suppliers means retraining staff and re-validating equipment, so once a hospital standardizes on a vendor it tends to stay. The company got much bigger in 2022 when it bought the Smiths Medical business from Smiths Group for roughly $2.35 billion, adding syringe and ambulatory pumps plus home-infusion products. That deal doubled its size but also loaded it with debt and brought integration headaches — a factory shutdown and quality problems at a Smiths plant squeezed supply and profits afterward, and the company has been working through recalls and remediation since. Rivals include bigger, diversified players like Becton, Dickinson and Baxter International.
The business is simple at its core: hospitals must keep patients hydrated and medicated, and the consumables get used up and bought again. That gave ICU Medical about $2.3 billion in revenue in 2024. The catch is that it's a low-margin, manufacturing-heavy business selling to hospitals that negotiate hard, and the debt from the Smiths deal limits its flexibility. It's a picks-and-shovels supplier to healthcare — unglamorous, essential, and only as good as its factories and its relationships with hospital purchasing departments.
Saved answer · last researched 15 Nov 2026